Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
REHOVOT, Israel, Sept. 07, 2017 -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that Amir London, Chief Executive Officer, will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 3rd Annual Healthcare Conference.
| Cantor Fitzgerald Global Healthcare Conference | ||
| Date: | Monday, September 25 | |
| Time: | 3:00pm Eastern Time | |
| Location: | InterContinental New York Barclay Hotel, New York City, Grand Ballroom #2 | |
| Webcast: | http://wsw.com/webcast/cantor6/kmda/ | |
| Ladenburg Thalmann 3rd Annual Healthcare Conference | ||
| Date: | Tuesday, September 26 | |
| Time: | 8:30am Eastern Time | |
| Location: | Sofitel New York Hotel, Odeon Ballroom | |
About Kamada
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company’s flagship product is GLASSIA®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets GLASSIA® in the U.S. through a strategic partnership with Baxalta (now part of Shire plc) and in other counties through local distributors. In addition to GLASSIA®, Kamada has a product line of seven other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency. In addition, Kamada's intravenous AAT is in development for other indications, such as type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada's rabies immune globulin (Human) product received FDA approval for Post-Exposure Prophylaxis against rabies infection in August 2017. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 complementary products in Israel that are manufactured by third parties.
CONTACTS: Gil Efron Deputy CEO & Chief Financial Officer [email protected] Bob Yedid LifeSci Advisors, LLC 646-597-6989 [email protected]
